Possibility of application of the disk diffusion method for studying the sensitivity of coagulase-negative staphylococcus to ceftaroline

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Ceftaroline is a modern broad-spectrum antibiotic (generation V of cephalosporin), an active metabolite of ceftaroline fosamil. The bactericidal effect of the drug is due to its high affinity of penicillin-binding protein PSP2a (mecA gene), which is responsible for the resistance of staphylococcus strains to methicillin. To determine the antibiotic sensitivity of microorganisms in the bacteriological laboratories of the Russian Federation, the disk diffusion method is widely used, which determines the sensitivity categories as resistant, moderately resistant, or sensitive. However, for several antibacterial drugs, including ceftaroline, criteria for assessing the efficiency only for Staphylococcus aureus are regulated, although coagulase-negative staphylococci (CoNS) are capable to cause various nosocomial infections and are a reservoir of mobile genetic elements determining staphylococci resistance to beta-lactam antibiotics. In cases of testing the sensitivity of CoNS to ceftaroline without established criteria for sensitivity/resistance, doctors cannot interpret the results reliably. In our study, we analyzed the sensitivity of 227 strains of seven CoNS species to ceftaroline. In 93.4% of cases, Staphylococcus epidermidis cultures were identified, and Staphylococcus saprophyticus and Staphylococcus lungdunensis were detected in 3.1% and 2.2% of cases, respectively. Based on the difference in the control points for cefoxitin for S. aureus and S. epidermidis, we proposed options for evaluating the sensitivity/resistance to ceftaroline for CoNS strains. In accordance with these criteria, 88.4% of the cultures selected demonstrated sensitivity to the drug. Moreover, 97.5% of the strains of methicillin-sensitive S. epidermidis were sensitive to ceftaroline, and only 2.5% were moderately resistant. Resistance to ceftaroline was demonstrated by 4.5% of methicillin-resistant S. epidermidis isolates, which in turn were characterized by poly- and pan-resistance. Representatives of the other six species being studied were sensitive to ceftaroline in 100% of cases. The results confirm the high activity of ceftaroline against CoNS. The proposed evaluation criteria interpreted the results more accurately, supplemented the existing antibioticograms, and used ceftaroline in treatment of infections caused by such bacteria.

Full Text

Restricted Access

About the authors

Svetlana A. Bozhkova

R.R. Vreden Russian Research Institute of Traumatology and Orthopedics

Author for correspondence.
Email: emgordina@win.rniito.ru
ORCID iD: 0000-0002-2083-2424

MD, PhD, DSc

Russian Federation, St. Petersburg

Ekaterina M. Gordina

R.R. Vreden Russian Research Institute of Traumatology and Orthopedics

Email: emgordina@win.rniito.ru
ORCID iD: 0000-0003-2326-7413


Russian Federation, St. Petersburg

Olga V. Shneider

R.R. Vreden Russian Research Institute of Traumatology and Orthopedics

Email: emgordina@win.rniito.ru
ORCID iD: 0000-0001-8341-2454


Russian Federation, St. Petersburg


  1. Guidelines for Susceptibility Testing of Microorganisms to Antibacterial Agents. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2004;6(4):306-59. (In Russian)
  2. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. Available at: http://www.eucast.org (accessed 15 April 2020).
  3. Vandepitte J., Engbaek K., Rohner P., Piot P., Heuck C.C. Basic Laboratory Procedures in Clinical Bacteriology. 2nd ed. World Health Organization; 2003:109-28.
  4. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2017.
  5. Central Asian and Eastern European surveillance of antimicrobial resistance. Annual report. WHO; 2016. 134 p.
  6. Reshed’ko G.K., Stetsyuk O.U. Features of determining the sensiti¬vity of microorganisms by the disk diffusion method. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2001;3(4):348-54. (In Russian)
  7. Sader H.S., Farrell D.J., Flamm R.K., Streit J.M., Mendes R.E., Ronald N.J. Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals. Diagn Microbiol Infect Dis. 2016;85(1):80-4. doi: 10.1016/j.diagmicrobio.2016.01.010.
  8. Dmitrenko O.A., Ankirskaya A.S., Lyubasovskaya L.A., Kovali¬shena O.V., Popov D.A., et al. Structural polymorphism of genome islands encoding resistance to beta-lactams in coagulase-negative staphylococci isolated at hospitals of the Russian Federation. Antibiotiki i khimioterapiya. 2015;60(7-8):3-10. (In Russian)
  9. Kozlova N.S., Barantsevich N.E., Ivanova L.V. Goik V.G., Schwartz A.P., Mokrova E.V. et al. Susceptibility to antibiotics in nosocomial staphylococci from multidisciplinary hospital. Problemy meditsinskoi mikologii. 2015;17(4):58-62. (In Russian)
  10. Morrissey I., Leakey А., Northwood J.B. In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008–2009. Int J Antimicrob Agents. 2012;40(3):227-34. doi: 10.1016/j.ijantimicag.2012.05.014.
  11. Granichnaya N.V., Zaitseva E.A., Perelomova O.V. Resistance of coagulase-negative staphylococci recovered from different biomaterials in cardiac patients. Tikhookeanskii meditsinskii zhurnal. 2019; (2):38-42. (In Russian)
  12. Destache C.J., Guervil D.J., Kaye K.S. Сeftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. Int J Antimicrob Agents. 2019;53(5):644-9. doi: 10.1016/j.ijantimicag.2019.01.014.
  13. Kozlov R.S., Golub A.V. Ceftaroline – sui generis. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2013;15(2):124-30. (In Russian)
  14. File T.M., Wilcox M.H., Stein G.E. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55(3): 173-80. doi: 10.1093/cid/cis559.
  15. Brown S.D., Traczewski M.M. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother. 2009;53(3): 1271-4. doi: 10.1128/AAC.01021-08.
  16. Mushtaq S., Warner M., Ge Y., Kaniga K., Livermore D.M. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother. 2007;60(2):300-11. doi: 10.1093/jac/dkm150.
  17. Saravolatz L.D., Stein G.E., Johnson L.B. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2011;52(9):1156-63. doi: 10.1093/cid/cir147.
  18. Gostev V.V., Popenko L.N., Chernenkaya T.V., Naumenko S.Z., Voroshilova T.M., Khokhlova O.E. et al. Estimation of MRSA susceptibility to oxacillin, cefoxitine, vancomycin and daptomyci. Antibiotiki i khimioterapiya. 2013;58(9-10):13-20. (In Russian)
  19. Kozlov R.S., Sukhorukova M.V., Sidorenko S.V., Eidelstein M.V., Skleenova E.Yu., Ivanchik N.V. et al. In vitro Ceftaroline activity against major bacterial pathogens in Russia: results of multicenter study. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2015;17(3):217-26. (In Russian)
  20. Roujansky A., Mathieu M., Camille G., Anne H., Roman M. Multidrug-resistant staphylococcus epidermidis ventriculostomy-related infection successfully treated by intravenous ceftaroline after failure of daptomycin treatment. World Neurosurg. 2020;136:221-5. doi: 10.1016/j.wneu.2020.01.013.

Supplementary files

Supplementary Files
1. Fig. 1. Sensitivity of S. epidermidis strains (%) to tested antibacterial drugs (EUCAST).

Download (252KB)

Copyright (c) 2020 Eco-Vector

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 01016 от 19.07.1995 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80632 от 15.03.2021 г

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies